New Treatment Options for Patients with Bladder Cancer
A number of new treatment options for different stages of bladder cancer are on the horizon, which will make education about the data behind these therapies and how they might be used in clinical practice important. Of interest, a number of treatment options for bacillus Calmette Guérin (BCG)-unresponsive non–muscle invasive bladder cancer (NMIBC) are currently being evaluated in clinical trials, and systemic therapy options for muscle-invasive and metastatic disease have rapidly expanded.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Category
  • Bladder Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation